1. Short title This Act may be cited as the Support And Value Expectant Moms and Babies Act of 2023 or the SAVE Moms and Babies Act of 2023 . 2. Abortion drugs prohibited (a) In general Section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) is amended by adding at the end the following: (z) Abortion drugs (1) Prohibitions The Secretary shall not approve— (A) any application submitted under subsection (b) or (j) for marketing an abortion drug; or (B) grant an investigational use exemption under subsection (i) for— (i) an abortion drug; or (ii) any investigation in which the unborn child of a woman known to be pregnant is knowingly destroyed. (2) Previously approved abortion drugs If an approval described in paragraph (1) is in effect for an abortion drug as of the date of enactment of the Support And Value Expectant Moms and Babies Act of 2023 , the Secretary shall— (A) not approve any labeling change— (i) to approve the use of such abortion drug after 70 days gestation; or (ii) to approve the dispensing of such abortion drug by any means other than in-person administration by the prescribing health care practitioner; (B) treat such abortion drug as subject to section 503(b)(1); and (C) require such abortion drug to be subject to a risk evaluation and mitigation strategy under section 505–1 that at a minimum— (i) requires health care practitioners who prescribe such abortion drug— (I) to be certified in accordance with the strategy; and (II) to not be acting in their capacity as a pharmacist; (ii) as part of the certification process referred to in clause (i), requires such practitioners— (I) to have the ability to assess the duration of pregnancy accurately; (II) to have the ability to diagnose ectopic pregnancies; (III) to have the ability to provide surgical intervention in cases of incomplete abortion or severe bleeding; (IV) to have the ability to ensure patient access to medical facilities equipped to provide blood transfusions and resuscitation, if necessary